Drug Name: | Abciximab |
---|---|
Drug Class: | Glycoprotein IIb/IIIa inhibitor |
Mechanism of Action: | Blocks the platelet glycoprotein IIb/IIIa receptor, preventing platelet aggregation |
Use: | Prevention of ischemic complications in patients undergoing percutaneous coronary intervention (PCI) |
Side Effects: |
|
Contraindications: | Active internal bleeding, recent major surgery, history of stroke within 30 days |
Specialty: |
|